Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

A review of needle-free sumatriptan injection for rapid control of migraine. Headache 2013 Sep;53 Suppl 2:21-33 PMID: 24024600

Pubmed ID

24024600

Abstract

The treatment of migraine was transformed in 1992 with the introduction of the first triptan-based therapy, subcutaneous (SC) sumatriptan. SC sumatriptan has high efficacy and a rapid onset of action compared with other available triptans and formulations presumably because of its short Tmax, high Cmax, and avoidance of enteral absorption. Because of these characteristics, SC sumatriptan is still considered the most reliably and rapidly effective self-administered medication available for acute migraine. Even so, it is relatively little used possibly in part because of patient "needle-phobia." The needle-free sumatriptan injection system (Sumavel DosePro) was developed to address this concern. Clinical trials have shown that the needle-free system is bioequivalent to needle-based injection systems, easy to use, and capable of providing rapid and effective symptom relief for many migraine episodes. Sumavel DosePro is an effective treatment for migraine and should be part of the therapeutic armamentarium, particularly in cases where a rapid onset of action is critical or where oral administration is problematic.

Author List

Rothrock JF, Freitag FG, Farr SJ, Smith EF 3rd

Author

Frederick G. Freitag DO Associate Professor in the Neurology department at Medical College of Wisconsin




Scopus

2-s2.0-84893974314   3 Citations

MESH terms used to index this publication - Major topics in bold

Animals
Chemistry, Pharmaceutical
Drug Delivery Systems
Humans
Injections, Subcutaneous
Migraine Disorders
Serotonin 5-HT1 Receptor Agonists
Sumatriptan
Time Factors
Treatment Outcome
jenkins-FCD Prod-297 dff1a717c492f00bf6291286365f1f4fe95208f1